| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteogenesis | 17 | 2015 | 104 | 2.360 |
Why?
|
| Transforming Growth Factor beta | 11 | 2014 | 87 | 2.040 |
Why?
|
| Femur | 17 | 2015 | 375 | 1.580 |
Why?
|
| Ultrasonic Therapy | 5 | 2017 | 24 | 1.360 |
Why?
|
| Rats | 33 | 2021 | 660 | 1.350 |
Why?
|
| Bone Morphogenetic Protein 2 | 7 | 2014 | 46 | 1.330 |
Why?
|
| Rats, Sprague-Dawley | 28 | 2021 | 328 | 1.250 |
Why?
|
| Bone Morphogenetic Proteins | 7 | 2015 | 69 | 1.220 |
Why?
|
| Animals | 52 | 2021 | 3681 | 1.150 |
Why?
|
| Prostheses and Implants | 11 | 2020 | 154 | 1.140 |
Why?
|
| Bone Regeneration | 10 | 2015 | 69 | 1.120 |
Why?
|
| Osteoporosis | 4 | 2020 | 77 | 1.080 |
Why?
|
| Osseointegration | 6 | 2021 | 67 | 0.930 |
Why?
|
| Bone Marrow Cells | 9 | 2010 | 53 | 0.880 |
Why?
|
| Titanium | 11 | 2021 | 169 | 0.800 |
Why?
|
| Awards and Prizes | 1 | 2022 | 22 | 0.760 |
Why?
|
| Mentoring | 1 | 2022 | 28 | 0.730 |
Why?
|
| Stromal Cells | 4 | 2010 | 34 | 0.720 |
Why?
|
| Implants, Experimental | 6 | 2021 | 32 | 0.690 |
Why?
|
| Fracture Healing | 4 | 2017 | 32 | 0.630 |
Why?
|
| Bone and Bones | 10 | 2017 | 117 | 0.600 |
Why?
|
| Prosthesis Failure | 5 | 2020 | 520 | 0.510 |
Why?
|
| Gene Expression Regulation | 4 | 2014 | 290 | 0.480 |
Why?
|
| Bone Marrow | 3 | 2015 | 76 | 0.470 |
Why?
|
| X-Ray Microtomography | 8 | 2021 | 80 | 0.460 |
Why?
|
| Gene Expression Profiling | 5 | 2010 | 143 | 0.460 |
Why?
|
| Disease Models, Animal | 7 | 2017 | 606 | 0.460 |
Why?
|
| Prosthesis Implantation | 2 | 2012 | 27 | 0.460 |
Why?
|
| Osteoblasts | 8 | 2015 | 57 | 0.450 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 56 | 0.440 |
Why?
|
| Recombinant Proteins | 8 | 2014 | 183 | 0.440 |
Why?
|
| Calcitonin | 1 | 2014 | 14 | 0.440 |
Why?
|
| Fracture Fixation | 1 | 2014 | 21 | 0.430 |
Why?
|
| Parathyroid Hormone | 1 | 2014 | 23 | 0.430 |
Why?
|
| Diphosphonates | 1 | 2014 | 16 | 0.430 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 14 | 0.430 |
Why?
|
| Osteoporotic Fractures | 1 | 2014 | 12 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 5 | 2012 | 178 | 0.420 |
Why?
|
| Cell Differentiation | 4 | 2010 | 137 | 0.420 |
Why?
|
| Osteolysis | 4 | 2020 | 139 | 0.410 |
Why?
|
| Receptors, CXCR4 | 2 | 2012 | 17 | 0.400 |
Why?
|
| Male | 31 | 2020 | 14887 | 0.380 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 9 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 331 | 0.360 |
Why?
|
| Gap Junctions | 1 | 2011 | 12 | 0.350 |
Why?
|
| Cell Communication | 1 | 2011 | 24 | 0.350 |
Why?
|
| Gene Expression | 5 | 2011 | 201 | 0.350 |
Why?
|
| Cells, Cultured | 10 | 2011 | 527 | 0.340 |
Why?
|
| Bone Remodeling | 4 | 2019 | 50 | 0.340 |
Why?
|
| Antibodies | 3 | 2015 | 46 | 0.320 |
Why?
|
| Ultrasonics | 2 | 2005 | 10 | 0.300 |
Why?
|
| Osteocytes | 3 | 2014 | 18 | 0.280 |
Why?
|
| Low-Level Light Therapy | 2 | 2017 | 4 | 0.280 |
Why?
|
| Bone Resorption | 5 | 2015 | 83 | 0.260 |
Why?
|
| Models, Animal | 10 | 2017 | 111 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 78 | 0.260 |
Why?
|
| Anabolic Agents | 1 | 2004 | 3 | 0.230 |
Why?
|
| Graft Survival | 1 | 2004 | 97 | 0.220 |
Why?
|
| Osteocalcin | 5 | 2019 | 27 | 0.220 |
Why?
|
| Genetic Markers | 2 | 2015 | 34 | 0.220 |
Why?
|
| Inflammation | 2 | 2020 | 287 | 0.220 |
Why?
|
| Biomarkers | 4 | 2019 | 561 | 0.210 |
Why?
|
| Heterocyclic Compounds | 2 | 2012 | 6 | 0.190 |
Why?
|
| Financing, Organized | 1 | 2022 | 8 | 0.190 |
Why?
|
| Ovariectomy | 3 | 2021 | 26 | 0.190 |
Why?
|
| Biocompatible Materials | 3 | 2014 | 89 | 0.190 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 37 | 0.190 |
Why?
|
| Biomechanical Phenomena | 5 | 2020 | 643 | 0.180 |
Why?
|
| Faculty, Medical | 1 | 2022 | 44 | 0.180 |
Why?
|
| Coated Materials, Biocompatible | 3 | 2007 | 41 | 0.180 |
Why?
|
| Bone Matrix | 2 | 2014 | 19 | 0.180 |
Why?
|
| Prosthesis Retention | 1 | 2020 | 4 | 0.170 |
Why?
|
| Bone-Implant Interface | 1 | 2020 | 7 | 0.170 |
Why?
|
| Humans | 18 | 2022 | 27307 | 0.170 |
Why?
|
| Signal Transduction | 3 | 2012 | 455 | 0.170 |
Why?
|
| Vitallium | 2 | 2011 | 27 | 0.170 |
Why?
|
| Myositis Ossificans | 1 | 1999 | 2 | 0.160 |
Why?
|
| Joint Prosthesis | 1 | 2020 | 89 | 0.160 |
Why?
|
| Body Weight | 1 | 2019 | 135 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2011 | 193 | 0.160 |
Why?
|
| Collagen | 4 | 2012 | 86 | 0.150 |
Why?
|
| Osteosarcoma | 1 | 1998 | 41 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 162 | 0.150 |
Why?
|
| Cartilage, Articular | 3 | 2008 | 419 | 0.140 |
Why?
|
| Prosthesis-Related Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
| Materials Testing | 5 | 2012 | 123 | 0.140 |
Why?
|
| Stem Cells | 1 | 2017 | 39 | 0.140 |
Why?
|
| Polymers | 2 | 2007 | 42 | 0.140 |
Why?
|
| Alloys | 3 | 2014 | 94 | 0.130 |
Why?
|
| Calcium Phosphates | 3 | 2005 | 17 | 0.130 |
Why?
|
| Polyethylene | 2 | 2019 | 124 | 0.130 |
Why?
|
| Biomimetic Materials | 2 | 2006 | 6 | 0.120 |
Why?
|
| Random Allocation | 2 | 2012 | 123 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 306 | 0.120 |
Why?
|
| Benzylamines | 2 | 2012 | 10 | 0.120 |
Why?
|
| Time Factors | 6 | 2014 | 1444 | 0.120 |
Why?
|
| Cobalt | 2 | 2014 | 109 | 0.120 |
Why?
|
| Cell Line | 5 | 2014 | 292 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2007 | 185 | 0.110 |
Why?
|
| Nickel | 1 | 2014 | 28 | 0.110 |
Why?
|
| Orthopedic Fixation Devices | 1 | 2014 | 19 | 0.110 |
Why?
|
| Nanotubes | 1 | 2014 | 9 | 0.110 |
Why?
|
| Wnt Proteins | 2 | 2012 | 23 | 0.110 |
Why?
|
| Thiophenes | 1 | 2014 | 10 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2014 | 49 | 0.110 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 17 | 0.110 |
Why?
|
| Matrix Metalloproteinases | 2 | 2010 | 19 | 0.100 |
Why?
|
| Transforming Growth Factor beta2 | 4 | 2006 | 13 | 0.100 |
Why?
|
| Fractures, Bone | 1 | 2014 | 75 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 60 | 0.100 |
Why?
|
| Bone Transplantation | 2 | 2005 | 203 | 0.100 |
Why?
|
| Female | 9 | 2021 | 15334 | 0.100 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2012 | 4 | 0.100 |
Why?
|
| Tensile Strength | 1 | 2012 | 23 | 0.100 |
Why?
|
| Surface Properties | 4 | 2019 | 131 | 0.100 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 161 | 0.100 |
Why?
|
| Reference Values | 1 | 2012 | 185 | 0.100 |
Why?
|
| Alkaline Phosphatase | 2 | 2010 | 19 | 0.100 |
Why?
|
| Cell Movement | 1 | 2012 | 82 | 0.100 |
Why?
|
| Electron Microscope Tomography | 1 | 2011 | 2 | 0.090 |
Why?
|
| NFATC Transcription Factors | 1 | 2011 | 10 | 0.090 |
Why?
|
| Calcineurin | 1 | 2011 | 9 | 0.090 |
Why?
|
| Radiation Dosage | 1 | 2011 | 37 | 0.090 |
Why?
|
| RNA, Messenger | 6 | 2005 | 317 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 12 | 0.090 |
Why?
|
| Transducers | 1 | 2010 | 10 | 0.090 |
Why?
|
| Matrix Metalloproteinase 13 | 2 | 2007 | 20 | 0.090 |
Why?
|
| Tissue Engineering | 2 | 2007 | 31 | 0.090 |
Why?
|
| Bayes Theorem | 1 | 2010 | 42 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 119 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2010 | 153 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2010 | 147 | 0.080 |
Why?
|
| Metals | 1 | 2011 | 139 | 0.080 |
Why?
|
| Equipment Design | 1 | 2010 | 136 | 0.080 |
Why?
|
| Extracellular Matrix | 2 | 2008 | 51 | 0.080 |
Why?
|
| Mice | 5 | 2015 | 1449 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2012 | 631 | 0.080 |
Why?
|
| Femoral Fractures | 2 | 2006 | 34 | 0.080 |
Why?
|
| Stress, Mechanical | 2 | 2007 | 157 | 0.080 |
Why?
|
| Chondrocytes | 2 | 2008 | 155 | 0.080 |
Why?
|
| Sialoglycoproteins | 2 | 2007 | 9 | 0.080 |
Why?
|
| Cartilage | 2 | 2008 | 103 | 0.080 |
Why?
|
| Growth Substances | 2 | 2005 | 28 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 146 | 0.070 |
Why?
|
| Freezing | 1 | 2008 | 14 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2001 | 57 | 0.070 |
Why?
|
| Cryopreservation | 1 | 2008 | 14 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2005 | 109 | 0.070 |
Why?
|
| Acrylic Resins | 1 | 2007 | 3 | 0.070 |
Why?
|
| Cell Culture Techniques | 2 | 2004 | 33 | 0.070 |
Why?
|
| Dactinomycin | 1 | 2007 | 7 | 0.070 |
Why?
|
| Cycloheximide | 1 | 2007 | 7 | 0.070 |
Why?
|
| Growth Differentiation Factor 5 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Guided Tissue Regeneration | 1 | 2006 | 11 | 0.070 |
Why?
|
| Phenotype | 2 | 2015 | 313 | 0.060 |
Why?
|
| Menisci, Tibial | 1 | 2008 | 173 | 0.060 |
Why?
|
| Durapatite | 1 | 2005 | 9 | 0.060 |
Why?
|
| Organ Preservation | 1 | 2005 | 7 | 0.060 |
Why?
|
| Genes, jun | 1 | 2005 | 4 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2005 | 5 | 0.060 |
Why?
|
| Osteonectin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Immediate-Early Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Osteopontin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Genes, myc | 1 | 2005 | 8 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 24 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 31 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2014 | 73 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2005 | 38 | 0.060 |
Why?
|
| Sodium Chloride | 1 | 2005 | 36 | 0.060 |
Why?
|
| Bone Marrow Purging | 1 | 2004 | 2 | 0.060 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 46 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2009 | 75 | 0.060 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 79 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2005 | 169 | 0.060 |
Why?
|
| Regeneration | 2 | 2015 | 18 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2012 | 3540 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 275 | 0.050 |
Why?
|
| Proteoglycans | 3 | 2008 | 133 | 0.050 |
Why?
|
| Cell Survival | 3 | 2008 | 121 | 0.050 |
Why?
|
| Dogs | 3 | 2008 | 151 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2015 | 454 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 130 | 0.050 |
Why?
|
| Hot Temperature | 2 | 2014 | 23 | 0.050 |
Why?
|
| Rats, Zucker | 1 | 2021 | 7 | 0.050 |
Why?
|
| Cell Death | 2 | 2014 | 49 | 0.050 |
Why?
|
| Retroviridae | 1 | 2001 | 5 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2001 | 20 | 0.040 |
Why?
|
| Cell Transplantation | 1 | 2001 | 21 | 0.040 |
Why?
|
| Bone Density | 2 | 2014 | 145 | 0.040 |
Why?
|
| Skull | 1 | 2001 | 21 | 0.040 |
Why?
|
| Adolescent | 3 | 2008 | 2185 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 667 | 0.040 |
Why?
|
| Cattle | 3 | 2008 | 124 | 0.040 |
Why?
|
| Osteogenesis, Distraction | 1 | 2000 | 9 | 0.040 |
Why?
|
| Calcification, Physiologic | 1 | 2019 | 18 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 1999 | 9 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1999 | 33 | 0.040 |
Why?
|
| Pedigree | 1 | 1999 | 55 | 0.040 |
Why?
|
| RNA | 1 | 1999 | 41 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 104 | 0.040 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 1998 | 1 | 0.040 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Oligonucleotide Probes | 1 | 1998 | 4 | 0.040 |
Why?
|
| Osteoclasts | 1 | 1999 | 22 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 1998 | 22 | 0.040 |
Why?
|
| Tretinoin | 1 | 1998 | 15 | 0.040 |
Why?
|
| Dinoprostone | 1 | 1998 | 16 | 0.040 |
Why?
|
| Cholecalciferol | 1 | 1998 | 7 | 0.040 |
Why?
|
| Arthroplasty, Replacement | 1 | 2020 | 150 | 0.040 |
Why?
|
| Actins | 1 | 1998 | 35 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 1998 | 49 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 1998 | 30 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 1999 | 65 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 124 | 0.040 |
Why?
|
| Adipocytes | 1 | 1997 | 22 | 0.040 |
Why?
|
| Infant | 1 | 1999 | 517 | 0.040 |
Why?
|
| In Situ Hybridization | 3 | 2005 | 50 | 0.040 |
Why?
|
| Child, Preschool | 1 | 1999 | 624 | 0.030 |
Why?
|
| Motor Activity | 1 | 2019 | 321 | 0.030 |
Why?
|
| Oligopeptides | 2 | 2007 | 21 | 0.030 |
Why?
|
| Hip Prosthesis | 1 | 2002 | 535 | 0.030 |
Why?
|
| Adult | 4 | 2008 | 7945 | 0.030 |
Why?
|
| Temperature | 2 | 2008 | 62 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2007 | 88 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2008 | 279 | 0.030 |
Why?
|
| DNA Primers | 2 | 2005 | 52 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2015 | 31 | 0.030 |
Why?
|
| Species Specificity | 1 | 2015 | 39 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 103 | 0.030 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2014 | 6 | 0.030 |
Why?
|
| Molybdenum | 1 | 2014 | 21 | 0.030 |
Why?
|
| Diaphyses | 1 | 2014 | 5 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 92 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2014 | 25 | 0.030 |
Why?
|
| Epitopes | 1 | 1994 | 44 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 43 | 0.030 |
Why?
|
| Interferometry | 1 | 2014 | 7 | 0.030 |
Why?
|
| Electrochemical Techniques | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2014 | 12 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2014 | 9 | 0.030 |
Why?
|
| Electrodes | 1 | 2014 | 14 | 0.030 |
Why?
|
| Water | 1 | 2014 | 29 | 0.030 |
Why?
|
| Chromium | 1 | 2014 | 86 | 0.030 |
Why?
|
| Cell Lineage | 2 | 2007 | 25 | 0.030 |
Why?
|
| Rabbits | 4 | 2000 | 180 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 225 | 0.030 |
Why?
|
| Humerus | 1 | 2014 | 107 | 0.030 |
Why?
|
| Periosteum | 1 | 2012 | 4 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2007 | 589 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2012 | 5 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2012 | 10 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 112 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 59 | 0.020 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 15 | 0.020 |
Why?
|
| Tibia | 1 | 2014 | 246 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 184 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 675 | 0.020 |
Why?
|
| Immunohistochemistry | 3 | 2000 | 375 | 0.020 |
Why?
|
| Calcineurin Inhibitors | 1 | 2011 | 16 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 415 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2011 | 80 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2011 | 119 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 617 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 117 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2009 | 11 | 0.020 |
Why?
|
| Cell Division | 2 | 2001 | 82 | 0.020 |
Why?
|
| Ossification, Heterotopic | 1 | 2009 | 35 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2014 | 391 | 0.020 |
Why?
|
| Apoptosis | 1 | 2009 | 216 | 0.020 |
Why?
|
| Preservation, Biological | 1 | 2008 | 4 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2008 | 28 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2008 | 15 | 0.020 |
Why?
|
| Compressive Strength | 1 | 2008 | 18 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2008 | 45 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 38 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2008 | 80 | 0.020 |
Why?
|
| Acrylates | 1 | 2007 | 2 | 0.020 |
Why?
|
| Ethylene Glycol | 1 | 2007 | 3 | 0.020 |
Why?
|
| Biomimetics | 1 | 2006 | 6 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 258 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 39 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 320 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2005 | 23 | 0.020 |
Why?
|
| Middle Aged | 3 | 2008 | 9068 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 168 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 2005 | 8 | 0.020 |
Why?
|
| Sulfates | 1 | 2005 | 4 | 0.020 |
Why?
|
| Shear Strength | 1 | 2005 | 7 | 0.020 |
Why?
|
| Hydroxyapatites | 1 | 2005 | 8 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2005 | 28 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2005 | 30 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 108 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 119 | 0.010 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2011 | 805 | 0.010 |
Why?
|
| Amino Acids | 1 | 2002 | 20 | 0.010 |
Why?
|
| Leukemia Virus, Murine | 1 | 2001 | 1 | 0.010 |
Why?
|
| Chemotaxis | 1 | 2001 | 6 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2001 | 9 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2001 | 13 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 25 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 45 | 0.010 |
Why?
|
| Transfection | 1 | 2001 | 121 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2002 | 4841 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2002 | 483 | 0.010 |
Why?
|
| Kidney | 1 | 2001 | 152 | 0.010 |
Why?
|
| Giant Cell Tumors | 1 | 1999 | 1 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1999 | 33 | 0.010 |
Why?
|
| Estrogen Receptor alpha | 1 | 1999 | 16 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1999 | 24 | 0.010 |
Why?
|
| Giant Cells | 1 | 1997 | 2 | 0.010 |
Why?
|
| Calcitriol | 1 | 1997 | 2 | 0.010 |
Why?
|
| Osteoarthritis | 1 | 2002 | 335 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1997 | 34 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 1999 | 131 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2002 | 1792 | 0.010 |
Why?
|
| Aged | 2 | 2002 | 9120 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 1999 | 383 | 0.010 |
Why?
|
| Immune Sera | 1 | 1994 | 5 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1994 | 25 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 1999 | 411 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1992 | 5 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1992 | 3 | 0.010 |
Why?
|
| Cornea | 1 | 1992 | 9 | 0.010 |
Why?
|